Komori
Fukoku (5185) · RiskFirst stated

Decline in Life Science orders due to tighter regulation of China's regenerative medicine system

First written in FY2027-H1. . Latest entry: FY2027-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Declining orders for related materials due to tighter regenerative medicine regulations in ChinaA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2027-H1First statedAnnual report

    「Life Science Business: Net sales decreased 18.6% year on year to ¥438 million, as the decline in orders for culture media and bags for China, associated with tighter regulation of China's regenerative medicine system, had a significant impact in the second quarter.」

    Tighter regulation of China's regenerative medicine system has resulted in an actual decline in orders for culture media and bags for China, affecting net sales and segment profit in the Life Science Business.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fukoku yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Decline in Life Science orders due to tighter regulation of China's regenerative medicine system | Fukoku Co.,Ltd. (5185) | Komori